Breaking News Instant updates and real-time market news.

RETA

Reata Pharmaceuticals

$85.00

9 (11.84%)

, ABBV

AbbVie

$74.21

0.92 (1.26%)

13:51
10/10/19
10/10
13:51
10/10/19
13:51

Reata Pharmaceuticals 'bold move' should be well received by Street, says Stifel

Stifel analyst Adam Walsh notes that in "a bold move" likely to be well received by the Street, Reata Pharmaceuticals (RETA) reacquired ex-U.S. rights to BARD, OMAV, and other Nrf2 activators from AbbVie (ABBV) for total deal consideration of $330M. Given AbbVie's lack of a significant renal franchise, the reacquisition of ex-U.S. BARD rights restores strategic flexibility to Reata and provides the opportunity to either find a more engaging development partner, go it alone ex-U.S., or sell the company outright, he contends. Further, the analyst believes the deal terms look "highly reasonable" relative to potential ex-U.S. BARD sales. Walsh has a Buy rating and $135 price target on Reata's shares.

RETA

Reata Pharmaceuticals

$85.00

9 (11.84%)

ABBV

AbbVie

$74.21

0.92 (1.26%)

  • 11

    Oct

  • 01

    Nov

RETA Reata Pharmaceuticals
$85.00

9 (11.84%)

08/08/19
JEFF
08/08/19
NO CHANGE
Target $128
JEFF
Buy
Reata change in trial analysis method 'may be slightly positive,' says Jefferies
Jefferies analyst Maury Raycroft said that Reata Pharmaceuticals' switch from using MMRM to an ANCOVA analysis in the Alport phase 3 trial "is not ideal optically," given that its late, but he sees some reasons the update "may be slightly positive." This, along with a stat change in FA, increases their chances of success, said Raycroft, would buy the shares here, "especially on any weakness." He keeps a Buy rating with a $128 price target on Reata.
08/16/19
SBSH
08/16/19
NO CHANGE
SBSH
Buy
Reata Pharmaceuticals 20% selloff brings buying opportunity, says Citi
With the August macro selloff, shares of Reata Pharmaceuticals are down 20% "absent fundamental changes" to the thesis, Citi analyst Yigal Nochomovitz tells investors in a research note. With two large Phase 3 catalysts coming by the end of 2019, the selloff provides a "clear opportunity" to buy the shares, says the analyst. He currently models an ~85% chance of the Alport Phase 3 working. Nochomovitz reiterates Reata as a "high conviction" top pick.
09/26/19
SBSH
09/26/19
NO CHANGE
SBSH
Buy
Citi opens 'Positive Catalyst Watch' on Reata Pharmaceuticals
Citi analyst Yigal Nochomovitz opened a 90-day "Positive Catalyst Watch" on Reata Pharmaceuticals ahead of the Phase 3 Cardinal data for bardoxolone in Alport syndrome expected in the second half of 2019. The analyst has a "high conviction" in Alport and expects the stock to be up ~50%-75% on positive data. He also expects investors to assign higher probabilities of success for bardoxolone in other rare nephropathies following the positive Alport data. He keeps a Buy rating on Reata shares.
09/26/19
NATL
09/26/19
INITIATION
Target $130
NATL
Buy
Reata Pharmaceuticals initiated with a Buy at National Securities
National Securities analyst Maria Barbera initiated Reata Pharmaceuticals with a Buy and $130 price target.
ABBV AbbVie
$74.21

0.92 (1.26%)

09/25/19
PIPR
09/25/19
NO CHANGE
Target $81
PIPR
Overweight
AbbVie survey supports above-consensus estimates, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on AbbVie (ABBV) shares with an $81 price target following a new rheumatologist survey by his firm's partners Spherix Global Insights. The survey indicates "robust" expectations for the company's oral JAK1 inhibitor Rinvoq, Raymond tells investors in a research note. Rheumatologists project that in six months, Rinvoq will leapfrog Eli Lilly's (LLY) Olumiant to become the second-most prescribed JAK with 5% share, says the analyst, citing the survey. He believes this supports his above-consensus Rinvoq revenue estimates.
09/26/19
SBSH
09/26/19
UPGRADE
SBSH
Buy
AbbVie upgraded to Buy from Neutral at Citi
Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral.
09/26/19
SBSH
09/26/19
UPGRADE
Target $90
SBSH
Buy
Citi upgrades AbbVie to Buy, sees 'significant' value from Allergan deal
Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral and raised his price target for the shares to $90 from $87. The analyst believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." Further, within AbbVie's organic portfolio, Baum continues to think the market underappreciates the revenue potential of both Skyrizi and Rinvoq.
09/26/19
09/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Square (SQ) upgraded to Outperform from Market Perform at Wells Fargo analyst Timothy Willi saying the company's fundamentals remain strong while investor sentiment is "overly negative and close to inflecting." 2. Whirlpool (WHR) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Rehaut saying he expects U.S. industry shipments to be more stable year-over-year through the end of 2019 and show "modest" growth in 2020. 3. Boston Beer (SAM) upgraded to Outperform from Market Perform at BMO Capital with analyst Amit Sharma saying Truly is "primed to capture" strong consumer demand and higher distribution/shelf space for hard seltzer. 4. AbbVie (ABBV) upgraded to Buy from Neutral at Citi with analyst Andrew Baum saying he believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." 5. Hologic (HOLX) upgraded to Buy from Neutral at BofA/Merrill with analyst Ivy Ma saying she sees the company being on "steadier footing with organic growth upside in FY20" thanks to its tuck-in acquisitions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

ACB

Aurora Cannabis

$3.68

-0.045 (-1.21%)

, USAT

USA Technologies

$0.00

(0.00%)

08:45
10/14/19
10/14
08:45
10/14/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

ACB

Aurora Cannabis

$3.68

-0.045 (-1.21%)

USAT

USA Technologies

$0.00

(0.00%)

BYND

Beyond Meat

$131.40

-4.6 (-3.38%)

CGC

Canopy Growth

$19.42

-1.005 (-4.92%)

CHK

Chesapeake

$1.38

0.09 (6.98%)

PZZA

Papa John's

$53.16

0.32 (0.61%)

NVAX

Novavax

$4.57

0.11 (2.47%)

DXJ

WisdomTree Japan Hedged Equity Fund

$51.12

1.1 (2.20%)

PTON

Peloton

$22.40

-0.755 (-3.26%)

UBER

Uber

$30.09

1.19 (4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 04

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 19

    Nov

NFLX

Netflix

$282.89

2.47 (0.88%)

08:42
10/14/19
10/14
08:42
10/14/19
08:42
Recommendations
Netflix analyst commentary  »

RBC Capital sees Q3 …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 29

    Oct

AKTX

Akari Therapeutics

$1.81

-0.03 (-1.63%)

08:42
10/14/19
10/14
08:42
10/14/19
08:42
Hot Stocks
Akari Therapeutics announces new data from ongoing Phase I/II AKC trial »

Akari Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PE

Parsley Energy

$16.98

0.52 (3.16%)

, JAG

Jagged Peak Energy

$6.81

0.16 (2.41%)

08:41
10/14/19
10/14
08:41
10/14/19
08:41
Hot Stocks
Parsley Energy sees Jagged Peak Energy deal immediately accretive on key metrics »

Key Transaction…

PE

Parsley Energy

$16.98

0.52 (3.16%)

JAG

Jagged Peak Energy

$6.81

0.16 (2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

NVST

Envista

$27.87

-1.2 (-4.13%)

08:40
10/14/19
10/14
08:40
10/14/19
08:40
Initiation
Envista initiated  »

Envista initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVST

Envista

$27.87

-1.2 (-4.13%)

, DHR

Danaher

$138.78

0.1 (0.07%)

08:38
10/14/19
10/14
08:38
10/14/19
08:38
Initiation
Envista, Danaher initiated  »

Envista initiated with an…

NVST

Envista

$27.87

-1.2 (-4.13%)

DHR

Danaher

$138.78

0.1 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 07

    Nov

KALV

KalVista

$11.00

0.27 (2.52%)

, RGNX

Regenxbio

$39.53

0.65 (1.67%)

08:37
10/14/19
10/14
08:37
10/14/19
08:37
Recommendations
KalVista, Regenxbio, Kala Pharmaceuticals, Kodiak Sciences, Regeneron, Aerie Pharmaceuticals, Applied Genetic, Aldeyra, Adverum Biotechnologies, Clearside Biomedical, Ocugen analyst commentary  »

Ophthalmic therapies…

KALV

KalVista

$11.00

0.27 (2.52%)

RGNX

Regenxbio

$39.53

0.65 (1.67%)

KALA

Kala Pharmaceuticals

$3.45

-0.15 (-4.17%)

KOD

Kodiak Sciences

$18.24

1.34 (7.93%)

REGN

Regeneron

$301.02

2.56 (0.86%)

AERI

Aerie Pharmaceuticals

$20.15

2.45 (13.84%)

AGTC

Applied Genetic

$3.10

-0.08 (-2.52%)

ALDX

Aldeyra

$5.16

-0.09 (-1.71%)

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

CLSD

Clearside Biomedical

$0.76

0.0326 (4.47%)

OCGN

Ocugen

$1.51

-0.07 (-4.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 19

    Oct

  • 24

    Oct

  • 05

    Nov

  • 06

    Nov

PE

Parsley Energy

$16.98

0.52 (3.16%)

, JAG

Jagged Peak Energy

$6.81

0.16 (2.41%)

08:37
10/14/19
10/14
08:37
10/14/19
08:37
Hot Stocks
Parsley Energy, Jagged Peak Energy boards 'unanimously' approve merger »

The boards of directors…

PE

Parsley Energy

$16.98

0.52 (3.16%)

JAG

Jagged Peak Energy

$6.81

0.16 (2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

HPE

HP Enterprise

$14.35

0.24 (1.70%)

08:36
10/14/19
10/14
08:36
10/14/19
08:36
Upgrade
HP Enterprise rating change  »

HP Enterprise upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

GNUS

Genius Brands

$0.77

0.0025 (0.33%)

, BABA

Alibaba

$172.97

6.925 (4.17%)

08:35
10/14/19
10/14
08:35
10/14/19
08:35
Hot Stocks
Genius Brands, Alibaba partner to co-produce animated children's series »

Genius Brands…

GNUS

Genius Brands

$0.77

0.0025 (0.33%)

BABA

Alibaba

$172.97

6.925 (4.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 19

    Nov

PE

Parsley Energy

$16.98

0.52 (3.16%)

, JAG

Jagged Peak Energy

$6.81

0.16 (2.41%)

08:35
10/14/19
10/14
08:35
10/14/19
08:35
Hot Stocks
Parsley Energy sees FY20 CapEx $1.6B-$1.9B »

Parsley (PE) remains…

PE

Parsley Energy

$16.98

0.52 (3.16%)

JAG

Jagged Peak Energy

$6.81

0.16 (2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CUB

Cubic

$68.86

0.58 (0.85%)

, SAIC

SAIC

$84.56

1.05 (1.26%)

08:35
10/14/19
10/14
08:35
10/14/19
08:35
Hot Stocks
Cubic appoints Hilary Hageman as general counsel »

Cubic (CUB) announced the…

CUB

Cubic

$68.86

0.58 (0.85%)

SAIC

SAIC

$84.56

1.05 (1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 12

    Nov

BLPH

Bellerophon

$0.45

-0.0104 (-2.26%)

08:33
10/14/19
10/14
08:33
10/14/19
08:33
Hot Stocks
Bellerophon to present new data from Cohort 1 of Phase 2/3 study of INOpulse »

lpBellerophon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PE

Parsley Energy

$16.98

0.52 (3.16%)

08:33
10/14/19
10/14
08:33
10/14/19
08:33
Hot Stocks
Parsley Energy sees Q3 net oil production 91.2-91.7 MBo per day »

For the third quarter,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

AXAS

Abraxas Petroleum

$0.37

0.0069 (1.89%)

08:33
10/14/19
10/14
08:33
10/14/19
08:33
Earnings
Abraxas Petroleum broadens engagement with Petrie Partners »

Abraxas Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

PE

Parsley Energy

$16.98

0.52 (3.16%)

08:32
10/14/19
10/14
08:32
10/14/19
08:32
Hot Stocks
Parsley Energy to acquire Jagged Peak Energy in $2.27B all-stock transaction »

Parsley Energy (PE) and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

RARE

Ultragenyx

$42.77

1.08 (2.59%)

08:31
10/14/19
10/14
08:31
10/14/19
08:31
Hot Stocks
Ultragenyx announces FDA acceptance of NDA for UX007 »

Ultragenyx Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASML

ASML

$260.46

8.86 (3.52%)

08:31
10/14/19
10/14
08:31
10/14/19
08:31
Recommendations
ASML analyst commentary  »

ASML price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 19

    Nov

PE

Parsley Energy

$16.98

0.52 (3.16%)

, JAG

Jagged Peak Energy

$6.81

0.16 (2.41%)

08:30
10/14/19
10/14
08:30
10/14/19
08:30
Hot Stocks
Breaking Hot Stocks news story on Parsley Energy, Jagged Peak Energy »

Parsley Energy acquires…

PE

Parsley Energy

$16.98

0.52 (3.16%)

JAG

Jagged Peak Energy

$6.81

0.16 (2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

DRYS

DryShips

$5.25

(0.00%)

, NCI

Navigant Consulting

$28.00

(0.00%)

08:30
10/14/19
10/14
08:30
10/14/19
08:30
Options
Four option delistings on October 14th »

Option delistings…

DRYS

DryShips

$5.25

(0.00%)

NCI

Navigant Consulting

$28.00

(0.00%)

TYPE

Monotype Imaging

$19.85

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHI

Omega Healthcare

$42.40

0.15 (0.36%)

08:29
10/14/19
10/14
08:29
10/14/19
08:29
Initiation
Omega Healthcare initiated  »

Omega Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NFLX

Netflix

$282.89

2.47 (0.88%)

08:25
10/14/19
10/14
08:25
10/14/19
08:25
Recommendations
Netflix analyst commentary  »

Morgan Stanley stays…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 29

    Oct

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:24
10/14/19
10/14
08:24
10/14/19
08:24
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:24
10/14/19
10/14
08:24
10/14/19
08:24
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:24
10/14/19
10/14
08:24
10/14/19
08:24
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.